Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03842228
Title Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

Advanced Solid Tumor

Therapies

Copanlisib + Durvalumab + Olaparib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST